Did Moderna and Merck Just Change the Future of Cancer Treatment Forever?

This week, shares of Moderna (NASDAQ: MRNA) surged following the announcement of landmark Phase 3 INTerpath-001 trial results alongside Merck (NYSE: MRK). While the stock experienced a natural cooldown today as short-term traders locked in profits, the underlying clinical paradigm shift is impossible to ignore.

The trial achieved the world's first successful Phase 3 result for a personalized mRNA cancer therapy, pairing intismeran autogene with Keytruda to target up to 34 patient-specific tumor mutations in high-risk resected melanoma.

Key clinical leaders highlighted the historic weight of the readout:

• Stéphane Bancel (CEO, Moderna) noted that turning an aspirational custom therapy into clinical reality marks a pivotal moment for cancer care.

• Dr. Dean Y. Li, MD, PhD (President, Merck Research Laboratories) emphasized how individualized neoantigen therapies have the potential to redefine standard treatment protocols.

• Dr. Kyle Holen (SVP & Head of Oncology Development, Moderna) highlighted that this is the first combination therapy to demonstrate a significant benefit over Keytruda alone in adjuvant melanoma.

The rapid trading volume and stock movement, tracked closely by financial intelligence provider Quiver Quantitative, has prompted extensive re-evaluation across Wall Street. Equity research teams at Citi Equity Research, Jefferies, and William Blair are already analyzing what this late-stage proof-of-concept means for broader solid tumor pipelines, including non-small cell lung cancer.

US Antimony Authorizes $100 Million Share Buyback to Counter Market Discount

When corporate valuation disconnects from critical mineral realities, industry leaders step up. United States Antimony Corporation (NYSE: UAMY) Chairman & CEO Gary C. Evans announced a unanimous board decision to approve a $100 million share repurchase program, citing that recent equity pricing severely undervalues the company's assets across the U.S., Canada, and Mexico.

Despite temporary top-line headwinds from delayed contract deliveries to the Defense Logistics Agency, institutional coverage remains bullish. Heiko Ihle, CFA, equity research analyst at H.C. Wainwright & Co., LLC., maintains a Buy rating on the stock, reinforcing confidence in the firm's North American production footprint. This capital allocation strategy aligns with broader sector moves, where peers like Almonty Industries Inc (NASDAQ: ALM) are also shoring up equity valuations during commodity pullbacks.

Are institutional investors sleeping on Western critical mineral independence?

Drilling Underway at Greenheart Gold's Tosso Creek Project After 13% Market Surge

Greenheart Gold (TSXV: GHRT | OTCQX: GHRTF) has officially mobilized core rigs for an initial 2,000-meter diamond drilling program at its flagship Tosso Creek Project in Suriname.

Led by President & CEO Justin van der Toorn alongside an executive team formerly with Reunion Gold, noted for discovering the multi-million-ounce Oko West deposit in Guyana, the company is leveraging deep Guiana Shield expertise along the prospective Paramaka Formation near the Sara Kreek gold fields.

The drill campaign is currently testing for depth continuity and structural controls at the central Walaba target before moving to the newly identified Swalanga target. Recent surface trenching set a strong foundation for the program, returning standout intercepts including 56.0 meters @ 0.97 g/t Au at Swalanga and 7.0 meters @ 4.57 g/t Au at Walaba, while initial exploration also continues across the Maconia and Sevil targets.

Can Justin van der Toorn and the former Reunion Gold leadership team unlock the Guiana Shield's next major gold discovery at depth?

Equinox Gold Receives Key BLM Approval for Nevada’s South Railroad Project

Equinox Gold Corp. (TSX: EQX, NYSE American: EQX) has officially secured its federal Record of Decision from the U.S. Bureau of Land Management (BLM) for the South Railroad project in Nevada, clearing the runway for early construction.

President Jason Simpson highlighted South Railroad as the first major organic step toward adding 800,000 ounces of annual production. 

This regulatory win lands just weeks after closing a transformative combination with Orla Mining, establishing the combined platform as Canada’s second-largest gold producer behind Agnico Eagle Mines Limited (TSX: AEM, NYSE: AEM).

Adding further conviction, founder and Chairman Emeritus Ross Beaty recently acquired C$9.7M in shares on the open market, signaling strong internal alignment as project execution ramps up.

With federal approvals locked in and construction underway, do you see Equinox Gold positioned for a major market re-rating?

Thanks for reading this week's newsletter!

We appreciate you taking the time to stay informed and ahead of the game.